Somatomedin-1 (recombinant insulin-like growth factor-1): Clinical pharmacology and potential treatment of endocrine and metabolic disorders

BioDrugs

Volumn 11, Issue 1, 1999, Pages 55-70

  Laron, Zvi ^a  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE; INSULIN; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; HEART DISEASE; HEMATOLOGIC DISEASE; HORMONE SUBSTITUTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LARON SYNDROME; LIPOPROTEIN BLOOD LEVEL; METABOLIC DISORDER; MITOGENESIS; NERVE GROWTH; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032929375     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199911010-00006     Document Type: Review

References (122)

1. 1. Merimee T, Laron Z. Growth hormone, IGF-I and growth: New views of old concepts. London-Tel Aviv: Freund Publishing House Ltd, Mod Endocrinol Diabetes 1996
2. 2. Blundell TL, Humbel RE. Hormone families: pancreatic hormones and homologous growth factors. Nature 1980; 287: 781-7
3. 3. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin like growth factor I and its structural homology with proinsulin. J Biol Chem 1978; 253: 2769-76
4. 4. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34
5. 5. Zapf J, Gosteli-Peter M, Schmid C. Insulin-like growth factor binding proteins (IGFBPs). In: Merimee T, Laron Z, editors. Growth hormone, IGF-I and growth: new views of old concepts. London-Tel Aviv: Freund Publishing House Ltd., Mod Endocrinol Diabetes 1996: 45-71
6. 6. Kaneti H, Silbergeld A, Klinger B, et al. Long-term effects of insulin-like growth factor (IGF)-I on serum IGF-I, IGF-binding protein-3 and acid labile subunit in Laron syndrome patients with normal growth hormone binding protein. Eur J Endocrinol 1997; 137: 626-30
7. 7. LeRoith D, Werner H, Beitner-Johnson D, et al. Molecular biology of IGF-I receptor. In: Merimee T, Laron Z, editors. Growth hormone, IGF-I and growth: new views of old concepts. London-Tel Aviv: Freund Publishing House Ltd., Mod Endocrinol Diabetes 1996: 73-99
8. 8. Adamo ML. Regulation of insulin-like growth factor I gene expression. Diabetes Rev 1995; 3: 2-27
9. 9. Bach LA, Rechler MM. Insulin-like growth factor binding proteins. Diabetes Rev 1995; 3: 38-61
10. 10. Silbergeld A, Litwin A, Bruchis S, et al. Insulin-like growth factor (IGF-I) in healthy children, adolescents and adults as determined by a radioimmunoassay specific for the synthetic 53-70 peptide region. Clin Endocrinol 1986; 25: 67-74
11. 11. Guler HP, Zapf J, Schmid C, et al. Insulin like growth factors I and II in healthy man. Estimations of half lives and production rates. Acta Endocrinol 1989; 121: 753-8
12. 12. Laron Z. Prismatic cases: Laron Syndrome (primary growth hormone resistance). From patient to laboratory to patient. J Clin Endocrinol Metab 1995; 80: 1526-73
13. 13. Phillips LS, Unterman TG. Somatomedin activity in disorders of nutrition and metabolism. In: Daughaday WH, editor. Clinics in endocrinology and metabolism: tissue growth factors. London: WB Saunders 1984: 145-89
14. 14. Niwa M, Sato Y, Saito Y, et al. Chemical synthesis, cloning and expression of genes for human somatomedin C (insulin like growth factor I) and 59Val somatomedin C. Ann NY Acad Sci 1986; 469: 31-52
15. 15. Laron Z. Somatomedin I in clinical use: facts and potential. Drugs 1993; 45: 1-8
16. 16. Clemmons DR, Underwood LE. Clinical review 59. Uses of human insulin-like growth factor-I in clinical conditions. J Clin Endocrinol Metab 1994; 79: 4-6
17. 17. Zapf J. Insulin-like growth factor (IGF)-I: an alternative for growth hormone (GH)? Int Growth Monit 1996; 6: 2-6
18. 18. Guler HP, Zapf J, Froesch ER. Short term metabolic effects of recombinant human insulin like growth factor in healthy adults. N Engl J Med 1987; 317: 137-40
19. 19. Froesch ER, Guler HP, Schmid C, et al. Therapeutic potential of insulin-like growth factor I. Trends Endocrinol Metab 1990; 1: 254-60
20. 20. Elahi D, McAloon-Dyke M, Fukagawa NK, et al. Hemodynamic and metabolic responses to human insulin like growth factor (IGF-I) in men. In: Spencer M, editor. Modern concepts of insulin like growth factor. Amsterdam: Elsevier Science, 1991: 219-24
21. 21. Zenobi PD, Graf S, Froesch ER. Effects of recombinant human insulin like growth factor I (rIGF-I) infusion on glucose tolerance, insulin levels and insulin secretion in man. [abstract no. 45]. Diabetes 1991; 40 (Suppl. I): 12A
22. 22. Takano K, Hizuka N, Asakawa K, et al. Effects of s.c. administration of recombinant insulin like growth factor I (IGF-I) on normal human patients. Endocrinol Jpn 1990; 37: 309-17
23. 23. Takano K, Hizuka N, Shizume K, et al. Repeated s.c. administration of recombinant insulin like growth factor I (IGF-I) to human patients for 7 days. Growth Regul 1991; 1: 23-8
24. 24. Laron Z, Klinger B, Erster B, et al. Effects of acute administration of insulin like growth. factor I in patients with Laron-type dwarfism. Lancet 1988; ii: 1170-2
25. 25. Laron Z, Klinger B, Silbergeld A, et al. Intravenous administration of recombinant IGF-I lowers serum GHRH and TSH. Acta Endocrinol 1990; 123: 378-82
26. 26. Laron Z, Blum W, Chatelain P, et al. Classification of growth hormone insensitivity syndrome. J Pediatr 1993; 122: 241
27. 27. Rosenfeld RG, Rosenbloom AL, Guevarra-Aguirre J. Growth hormone (GH) insensitivity to primary Gh receptor deficiency. Endocr Rev 1994; 15: 369-90
28. 28. Klinger B, Garty M, Silbergeld A, et al. Elimination characteristics of intravenously administered rIGF-I in Laron type dwarfs (LTD). Dev Pharmacol Ther 1990; 15: 196-9
29. 29. Eshet R, Dux Z, Silbergeld A, et al. Erythrocytes from patients with low serum concentrations of IGF-I have an increase in receptor sites for IGF-I. Acta Endocrinol (copenh) 1991; 125: 354-8
30. 30. Eshel R, Klinger B, Silbergeld A, et al. Modulation of insulin like growth factor I (IGF-I) binding sites on erythrocytes by IGF-I treatment in patients with Laron syndrome (LS). Regul Pept 1993; 48: 233-9
31. 31. Laron Z, Klinger B, Blum WF, et al. IGF binding protein 3 in patients with LTD: effect of exogenous rIGF-I. Clin Endocrinol 1992; 36: 301-4
32. 32. Gourmelen M, Perin L, Binoux M. Interest of IGF-I and IGF-BPs measurements in patients with Laron-type dwarfism. In: Laron Z, Parks JS, editors. Lessons from Larom Syndrome (LS) 1966-1992. Basel-New York: Karger, 1993: 181-184. Pediatric and Adolescent Endocrinology, vol. 24.
33. 33. Gil-Ad I, Koch Y, Silbergeld A, et al. Differential effect of insulin-like growth factor I (IGF-I) and growth hormone (GH) on hypothalamic regulation of GH secretion in the rat. J Endocrinol Invest 1996; 19: 542-7
34. 34. Laron Z, Klinger B, Jensen LT, et al. Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism. Clin. Endocrinol 1991; 35: 145-50
35. 35. Klinger B, Jensen LT, Silbergeld A, et al. Insulin-like growth factor-I raises serum procollagen levels in children and adults with Laron syndrome. Clin Endocrinol 1996; 45: 423-9
36. 36. Laron Z, Anin S, Klipper-Aubach Y, et al. Effects of insulin-like growth factor on linear growth, head circumference and body fat in patients writh Laron-type dwarfism. Lancet 1992; 339: 1258-61
37. 37. Walker JL, Van Wyk JJ, Underwood LE. Stimulation of statural growth by recombinant insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron type). J Pediatr 1992; 121: 641-6
38. 38. Klinger B, Laron Z. Renal function in Laron syndrome patients treated by insulin-like growth factor-I. Pediatr Nephrol 1994; 8: 684-8
39. 39. Kaneti H, Karasik A, Klinger B, et al. Long-term treatment of Laron type dwarfs with insulin-like growth factor I increases serum insulin-like growth factor - binding protein 3 in the absence of growth hormone activity. Acta Endocrinol 1993; 128: 144-9
40. 40. Rechler MM, Brown AL. Insulin-like growth factor binding proteins: gene structure and expression. Growth Regul 1992; 2: 55-68
41. 41. Klinger B, Anin S, Silbergeld A, et al. Development of hyperandrogenism during treatment with insulin-like growth factor-I (IGF-I) in female patients with Laron Syndrome. Clin Endocrinol 1998; 48: 81-87
42. 42. Ranke MB, Savage MO, Chatelain PG, et al. Insulin-like growth factor I improves height in growth hormone insensitivity: two years' results. Horm Res 1995; 44: 253-64
43. 43. Backeljauw PF, Underwood LE, the GHIS collaborative group. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome - a clinical research center study. J Clin Endocrinol Metab 1996; 81: 3312-7
44. 44. Klinger B, Laron Z. Three year IGF-I treatment of children with Laron Syndrome. J Pediatr Endocrinol Metab 1995; 8: 149-58
45. 45. Guevara-Aguirre J, Rosenbloom AL, Vasconez O, et al. Two year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor-I in 22 children: comparison of two dosage levels and to GH treated GH deficiency. J Clin Endocrinol Metab 1997; 82: 629-33
46. 46. Guevara-Aguirre J, Vasconez O, Martinez V, et al. A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency. J Clin Endocrinol Metab 1995; 80: 1393-8
47. 47. Laron Z, Klinger B. IGF-I treatment of adult patients with Laron syndrome: preliminary results. Clin Endocrinol 1994; 41: 631-8
48. 48. Oliviera SB, Arnhold IJP, Phillips JA III, et al. Treatment with recombinant IGF-I for patients with growth hormone (GH) gene deletion. [abstract no.8] Pediat Res 1997; 41: 301
49. 49. Bach LA, Rechler MM. Insulin-like growth factors and diabetes. Diabetes Metab Rev 1992; 8: 229-57
50. 50. Cheetham TD, Jones J, Taylor AM, et al. The effects of recombinant human insulin-like growth factor-I administration on growth hormone levels and insulin requirements in adolescents with type I (insulin dependent) diabetes mellitus. Diabetologia 1993; 36: 678-81
51. 51. Cheetham TD, Clayton KL, Taylor AM, et al. The effects of recombinant human insulin-like growth factor-I on growth hormone secretion in adolescents with insulin dependent diabetes mellitus. Clin Endocrinol 1994; 40: 515-22
52. 52. Bach MA, Chin E, Bondy CA. The effects of subcutaneous insulin-like growth factor-I infusion in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1994; 79; 1040-5
53. 53. Cheetham TD, Connors M, Clayton K, et al. The relationship between overnight GH levels and insulin concentrations in adolescents with insulin-dependent diabetes mellitus (IDDM) and the impact of recombinant human insulin-like growth factor I (rhIGF-I). Clin Endocrinol 1997; 46: 415-24
54. 54. Dunger DB, Cheetham TD, Holly JMP, et al. Does recombinant insulin-like growth factor-I have a role in the treatment of insulin-dependent diabetes mellitus during adolescence. Acta Paediatr Scand 1993; (Suppl) 388: 49-52
55. 55. Dunger DB, Acerini CL, Cheetham TD, et al. How does rhIGF-I replacement improve insulin sensitivity in insulin dependent diabetes mellitus? J Pediat Endocrinol Metab 1997; 10: 117-22
56. 56. Bereket A, Lang CH, Blethen SL, et al. Insulin-like growth factor binding protein-3 proteolysis in children with insulin-dependent diabetes mellitus: a possible role for insulin in the regulation of IGFBP-3 protease activity. J Clin Endocrinol Metab 1995; 80: 2282-8
57. 57. Acerini CL, Patton CM, Savage MO, et al. Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet 1997; 350: 1199-204
58. 58. Quattrin T, Thrailkill K, Baker L, et al. Dual recombinant replacement with insulin and recombinant human insulin-like growth factor I in IDDM. Diabetes Care 1997; 20: 374-80
59. 59. Thrailkill K, Quattrin T, Baker L, et al. Dual hormonal replacement therapy with insulin and recombinant human insulin like growth factor I (IGF-I) in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system. J Clin Endocrinol Metab 1997; 82: 1181-7
60. 60. Usala A-L, Madigan T, Burguera B, et al. Brief report: treatment of insulin-resistant diabetic ketoacidosis with insulin-like growth factor I in an adolescent with insulin-dependent diabetes. N Engl J Med 1992; 327: 853-7
61. 61. Longo N, Singh R, Griffin LD, et al. Impaired growth in Rabson-Mendenhall syndrome: lack of effect of growth hormone and insulin-like growth factor I. J Clin Endocrinol Metab 1994; 79: 799-805
62. 62. Usala A-L, Madigan T, Burguera B, et al. High dose intravenous, but not low dose subcutaneous insulin-like growth factor-I therapy induces sustained insulin sensitivity in severely resistant type I diabetes mellitus. J Clin Endocrinol Metab 1994; 70: 435-40
63. 63. Backeljauw PF, Alves C, Eidson M, et al. Effect of intravenous insulin-like growth factor I in two patients with leprechaunism, Pediatr Res 1994; 36: 749-54
64. 64. Schalch DS, Turman NJ, Maresisin VS, et al. Short-term effects of recombinant human insulin-like growth factor I on metabolic control of patients with type II diabetes mellitus. J Clin Endocrinol Metab 1993; 77: 1563-8
65. 65. Young SCJ, Clemmons DR. Changes in insulin-like growth factor (IGF)-binding proteins after IGF-I injections in non-insulin-dependent diabetics. J Clin Endocrinol Metab 1994; 78: 609-14
66. 66. Jabri N, Schalch DS, Schwartz SL, et al. Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients. Diabetes 1994; 43: 369-74
67. 67. Moses AC. Recombinant human insulin-like growth factor as a therapeutic agent for severe insulin resistance and type II diabetes mellitus. J Pediatr Endocrinol Metab 1997; 10: 123-30
68. 68. rhIGF-I in NIDDM study group. Evidence from a dose-ranging study that recombinant insulin-like growth factor-I (rhIGF-I) effectively and safely improves glycemic control in non-insulin dependent diabetes mellitus (NIDDM) [abstract no. 94] Diabetes 1996; 45 (Suppl. 2): 27A
69. 69. Laron Z, Karp M. Carbohydrate metabolism in the syndrome of familial dwarfism and high plasma immunoreactive growth hormone (Laron type dwarfism). In: Podolsky S, Wiswanathan M, editors. Secondary diabetes: the spectrum of the diabetic syndrome. New York: Raven Press, 1980: 363-71
70. 70. Laron Z, Avitzur Y, Klinger B. Carbohydrate metabolism in primary growth hormone resistance (Laron syndrome), before and during insulin-like growth factor I treatment. Metabolism 1995; 44 (Suppl 4): 113-8
71. 71. Laron Z, Avitzur Y, Klinger B. Carbohydrate metabolism in primary growth hormone resistance (Laron syndrome) before and during insulin-like growth factor-I treatment. J Pediatr Endocrinol Metab 1997; 10: 105-15
72. 72. Tamborlane WV, Hintz RL, Bergman M, et al. Insulin-infusion-pump treatment of diabetes: influence of improved metabolic control on plasma somatomedin levels. N Engl J Med 1981; 305: 303-7
73. 73. Annotations: insulin and insulin-like growth factors in diabetes mellitus. Arch Dis Child 1995; 72: 469-77
74. 74. Dahlen GH. Lp(a) lipoprotein in cardiovascular disease (Review). Atherosclerosis 1994; 108: 111-26
75. 75. Utermann G. The mysteries of lipoprotein(a). Rev Sci 1989; 246: 904-10
76. 76. Eden S, Oscarsson J. GH and IGF-I in lipoprotein metabolism. J Pediatr Endocrinol Metab 1997; 10: 137-41
77. 77. Laron Z, Wang XL, Silbergeld Z, et al. Growth hormone increases and insulin-like growth factor-I decreases circulating lipoprotein(a). Eur J Endocrinol 1997; 136: 377-81
78. 78. Laron Z, Klinger B, Silbergeld A, et al. Opposing effects of growth hormone and insulin-like growth factor I on serum lipoprotein. J Pediatr Endocrinol Metab 1997; 10: 143-9
79. 79. Hirschberg R, Kopple JD. Insulin-like growth factor I and renal function. Diabetes Rev 1995; 3: 177-95
80. 80. Laron Z, Wang XL, Klinger B, et al. Growth hormone treatment increases circulating lipoprotein(a) in children with chronic renal failure. J Pediatr Endocrinol Metab 1996; 9: 533-7
81. 81. Bondy CA, Lee W-H. Patterns of insulin-like growth factor and IGF receptor gene expression in the brain: functional implications. In: Raizada MK, LeRoith DL, editors. The role of insulin-like growth factors in the nervous system. Ann N Y Acad Sci 1993; 692: 33-43
82. 82. Raizada MK, LeRoith DL, editors. The role of insulin-like growth factors in the nervous system. Ann N Y Acad Sci 1993; 692: 33-43
83. 83. Gluckman PD, Guan J, Beilharz EJ, et al. The role of the insulin-like growth factor system in neuronal rescue. The role of insulin-like growth factors in the nervous system. In: Raizada MK, LeRoith DL, editors. The role of insulin-like growth factors in the nervous system. Ann N Y Acad Sci 1993; 692: 138-48
84. 84. Bozyczko-Coyne D, Glicksman MA, Prantner JE, et al. IGF-I supports the survival and/or differentiation of multiple types of central nervous system neurons. In: Raizada MK, LeRoith DL, editors. The role of insulin-like growth factors in the nervous system. Ann N Y Acad Sci 1993; 692: 311-3
85. 85. Carlsson-Skwirut C, Jornwall H, Holmgren A, et al. Isolation and characterization of varian IGF-I as well as ICF-2 from adult human brain FEBS Lett 1986; 201: 46-50
86. 86. Doyle KL, Sara VR, Plenderleith MB. Localisation of insulin-like growth faclor-I in spinal cord of rats following unilateral sciatic nerve transection. [abstract no. OR-24] In: 10th International Congress of Endocrinology: San Francisco, CA, USA, 1996: 459
87. 87. Reynolds R, Wong V, et al. Brain-derived neurotrophic factor and eurotrophin -4/5 stimulate proliferation and c-Fos expression in cultured ligodendroglial progenitors: synergism with insulin-like growth faclor-I 1997. In press
88. 88. Laron Z, Pertzelan A, Karp M. Pituitary dwarfism with high serum levels of growth hormone. Isr J Med Sci 1968; 4: 883-94
89. 89. Galatzer A, Aran O, Nagelberg N, et al. Cognitive and psychosocial functioning of young adults with Laron syndrome. In: Laron Z, Parks JS, editors. Lessons from Laron Syndrome (LS) 1966-1992. Pediatr Adolesc Endocrinol, Basel-New York: Karger, 1993: 53-60
90. 90. Woods KA, Fraser NC, Postel-Vinay MC, et al. A homozygous splice site mutation affecting the intracellular domain of the growth hormone (GH) receptor resulting in Laron syndrome with elevated GH-binding protein. J Clin Endocrinol Metab 1996; 81: 1686-90
91. 91. Laron Z, Lazar L, Galatzer A, et al. Growth hormone treatment accelerates head circumference growth in isolated GH deficiency. In: Hauspie R, Lindgren G, Falkner F, editors. Essays on Auxology. Hertfordshire, UK: Castlemead Publications, 1995: 489-95
92. 92. Kranzler JH, Rosenbloom AL, Martinez V, et al. Normal intelligence with severe insulin-like growth factor I deficiency due to growth hormone receptor deficiency. A controlled study in a genetically homogenous population. J Clin Endocrinol Metab 1998; 83: 1953-8
93. 93. Laron Z, Galatzer A. A comment on normal intelligence in growth hormone receptor deficiency. (Letter). J Clin Endocrinol Metab 1998; 83: December (In Press)
94. 94. Lai EC, Felice KJ, Festoff BW, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. Neurology 1997; 49: 1621-30
95. 95. Reid IR, Gluckman PD, Ibbertson HK. Insulin-like growth factor I and bone turnover in glucocortoid-treated and control subjects. Clin Endocrinol 1989; 30: 347-53
96. 96. Rubin CD, Reed B, Sakhaee K, et al. Treating a patient with Werner syndrome and osteoporosis using recombinant human insulin-like growth factor. Ann Int Med 1994; 121: 665-8
97. 97. Johansson AG, Lindh E, Blum WF, et al. Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis. J Clin Endocrinol Metab 1996; 81: 44-8
98. 98. Jenkins RC, Ross RJM. The use of growth hormone and insulin-like growth factor-I in catabolic states. J Pediatr Endocrinol Metab 1997; 10: 131-6
99. 99. Herndon DN, Barrow RE, Kunkel KR, et al. Effects of recombinant human growth hormone on donor site healing in severely burned children. Ann Surg 1990; 212: 424-31
100. 100. Gore DC, Honeycutt D, Jahoor F, et al. Effect of exogenous growth hormone on whole body and isolated limb protein kinetics in burned patients. Arch Surg 1991; 126: 38-43
101. 101. Krentz AJ, Koster FT, Crist DM, et al. Anthropometric, metabolic, and immunological effects of recombinant human growth hormone in AIDS and AIDS-related complex. J Acquir Immune Defic Syndr 1993; 6: 245-51
102. 102. Lieberman SA, Butterfield GE, Harrison D, et al. Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1994; 78: 404-10
103. 103. Cioffi WG, Gore DC, Rue LC, et al. Insulin-like growth factor-I lowers protein oxidation in patients with thermal injury. Ann Surg 1994; 220: 310-9
104. 104. Huang KF, Chung DH, Herndon DN. Insulin like growth factor I (IGF-I) reduces gut atrophy and bacterial translocation after severe burn injury. Arch Surg 1993; 128: 47-54
105. 105. Tashiro T, Yamamori H, Takagi K, et al. Effects of growth hormone and insulin-like growth factor I on protein metabolism after experimental burn injury. Endocrinol Metab 1996; 3 (Suppl A): 75
106. 106. Shimoda N, Tashiro T, Yamamori H, et al. Effects of growth hormone and insulin-like growth factor-I on protein metabolism, gut morphology, and cell-mediated immunity in burned rats. Nutrition 1997; 13: 540-6
107. 107. Goeters C, Mertes N, Tacke J, et al. Repeated administration of recombinant human insulin-like growth factor-I in patients after gastric surgery. Ann Surg 1995; 222: 646-53
108. 108. Miell JP, Taylor AM, Jones J, et al. Administration of human recombinant insulin-like growth factor-I to patients following major gastrointestinal surgery. Clin Endocrinol 1992; 37: 542-51
109. 109. Muta K, Krantz S, Bondourant MC, et al. Distinct roles of erythropoietin, insulin-like growth factor 1 and stem cell factor in the development of erythroid progenitor cells. J Clin Invest 1992; 94: 34-43
110. 110. Merchav S, Silvian-Drachsler I, Tatarsky I, et al. Comparative studies of the erythroid-potentiating effects of biosynthetic human insulin-like growth factors I and II. J Clin Endocrinol Metab 1992; 74: 447-52
111. 111. Zegers BJM, Merchav S. Growth hormone and insulin-like growth factors in haemopoiesis, lymphopoiesis and immune function. Endocrinol Metab 1996; 3 (Suppl. A): 105-9
112. 112. Merchav S, Tatarksy I, Hochberg Z. Enhancement of human granulopoiesis in vitro by biosynthetic insulin-like growth factor I/somatomedin C and human growth hormone. J Clin Invest 1988; 81: 791-7
113. 113. Merchav S, Lake M, Skottner A. Comparative studies of the granulopoietic enhancing effects of biosynthetic human insulin-like growth factors I and II. J Cell Physiol 1993; 157: 178-83
114. 114. Clark R, Strasser J, McCabe S, et al. Insulin-like growth factor-I stimulation of lymphopotesis. J Clin Invest 1993; 92: 540-8
115. 115. Landreth KS, Narayanan R, Dorshkind K. Insulin-like growth factor-I regulates pro-B cell differentiation. Blood 1992; 80: 1207-12
116. 3IGF-I stimulates visceral organ growth and proliferation of gut tissues in suckling rats. Am J Physiol 1997; 272 (Gastointest Liver Physiol 35): G522-33
117. 117. Fholenhag K, Arrhenius-Nyberg V, Sjogren I, et al. Effects of insulin-like growth factor I (IGF-I) on the small intestine: a comparison between oral and subcutaneous administration in the weaned rat. Growth Factors 1997; 14: 81-8
118. 118. Wolf E, Jehle PM, Weber MM, et al. Human insulin-like growth factor I (IGF-I) produced in the mammary glands of transgenic rabbits: yield, receptor binding, mitogenic activity, and effects on IGF-I binding proteins. Endocrinology 1997; 138: 307-13
119. 119. Wang YZ, Wong YC. Sex hormone-induced prostatic carcinogenesis in the noble rat: the role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. Prostate 1998; 35: 165-77
120. 120. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563-6
121. 121. Fleming RYD, Rutan RL, Jahoor F, et al. Effect of recombinant human growth hormone on catabolic hormones and free fatty acids following thermal injury. J Trauma 1992; 32: 698-703
122. 122. Kupfer SR, Underwood LE, Baxter RC, et al. Enhancement of the anabolic effect of growth hormone and insulin-like growth factor I by use of both agents simultaneously. J Clin Invest 1993; 91: 391-6